Who
Cheryl Cohen
Director
Company insider
Files Form 4 as: Director, ImmunityBio; Director, Celldex Therapeutics; Director, Lite Strategy; Director, Whitehawk Therapeutics; Director, Eledon Pharmaceuticals; Director, Immunic; Director, Cytrx; Chief Commercial Officer, Medivation.
In numbers
- Trades disclosed
- 74
- Buys
- 1
- Sells
- 12
- Bought
- $25K
- Sold
- $10.4M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 15 Sep 2011
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | $167K55,979 at $2.98 | filing |
| 2 Oct 2026filed 6 Oct 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $851K81,056 at $10.50 | filing |
| 2 Oct 2026filed 6 Oct 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —55,979 at $0.00 | filing |
| 2 Jul 2026filed 6 Jul 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | $167K55,979 at $2.98 | filing |
| 2 Jul 2026filed 6 Jul 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $1.2M131,210 at $9.50 | filing |
| 2 Jul 2026filed 6 Jul 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —55,979 at $0.00 | filing |
| 2 Jul 2026filed 6 Jul 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —55,979 at $0.00 | filing |
| 2 Jul 2026filed 6 Jul 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | $167K55,979 at $2.98 | filing |
| 2 Jul 2026filed 6 Jul 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Sold | $1.2M131,210 at $9.50 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —65,600 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —65,600 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —162,786 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —77,633 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,300 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —158,263 at $0.00 | filing |
| 5 Jul 2022filed 7 Jul 2022 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,500 at $0.00 | filing |
News
ImmunityBio (NASDAQ:IBRX) Director Cheryl Cohen Sells 81,056 Shares of Stocktickerreport.com · 7 Oct 2026ImmunityBio (NASDAQ:IBRX) Shares Down 6.4% – Here's WhyIBRX · dailypolitical.com · 19 Oct 2026
1 headline in the last 90 days name Cheryl Cohen; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.